絞り込み

16242

広告

「"Goetz MP "[Author]」の検索結果

94件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.

Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence.

Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy.

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance).

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Landscape of Neoadjuvant Therapy for Breast Cancer.

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies.

TBCRC 008: Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) predicts response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Sort by
※並べ替えは表示に時間がかかります